Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma

CD19-targeted chimeric antigen receptor (CAR) T cell therapy is an effective treatment for diffuse large B cell lymphoma (DLBCL). In addition to cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity (ICANS), B cell aplasia and hypogammaglobulinemia are common toxicities p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Cancer J
Main Authors: Wudhikarn, Kitsada, Palomba, M. Lia, Pennisi, Martina, Garcia-Recio, Marta, Flynn, Jessica R., Devlin, Sean M., Afuye, Aishat, Silverberg, Mari Lynne, Maloy, Molly A., Shah, Gunjan L., Scordo, Michael, Dahi, Parastoo B., Sauter, Craig S., Batlevi, Connie L., Santomasso, Bianca D., Mead, Elena, Seo, Susan K., Perales, Miguel-Angel
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7405315/
https://ncbi.nlm.nih.gov/pubmed/32759935
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-020-00346-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados